Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007154 | Immune System Diseases NIH | 0.41 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
DESIGN Longitudinal prospective observational multicentre study. Primary objective: Understand the immune mechanisms driving COVID-19 disease in patients with a history of lung disease
Description: Anti-viral cytokine protein concentration in blood samples by ELISA
Measure: Anti-viral cytokine levels in blood samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Inflammatory cytokine protein concentration in sputum samples by ELISA
Measure: Anti-viral cytokines profiles within sputum samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Inflammatory cytokine protein concentration in nasal lavage samples by ELISA
Measure: Anti-viral cytokine profiles within nasal lavage samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Inflammatory gene expression in upper airway respiratory epithelial cells by RNA sequencing.
Measure: Expression of inflammatory gene expression in upper respiratory epithelial airway cells using nasal brush specimens in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Analysis of viral components recognized by the adaptive immune system
Measure: Identify the T cell antigens and B cell epitopes in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Cytokine protein concentration following PBMC stimulation to pathogen recognition receptor agonists by Elispot
Measure: Peripheral blood mononuclear cell (PBMC) interferon mediated immune responses to pathogen recognition receptor agonists in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Analysis of endothelial function
Measure: Identify endothelial function in chronic respiratory disease associated with susceptibility to severe COVID-19 infection using EndoPAT testing Time: Through study completion an average of 1 yearDescription: Serum and plasma protein concentration of endothelial cell inflammation biomarkers by ELISA
Measure: Endothelial cell inflammation biomarkers in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Analysis of sputum microbiome
Measure: Identify sputum 16S rRNA and ITS sequences in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Analysis of nasal microbiome
Measure: Identify nasal lavage 16S rRNA and ITS sequences in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Study participant survey
Measure: Identify quality of life markers in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports